Sopharma

Sopharma’s 2022 net profit down by 15%

Leading pharmaceuticals manufacturer and distributor Sopharma posted a slowdown in terms of net profit, down by 15% YoY to BGN 77.9M. This is mainly due to acquisition of and exemption from subsidiaries in the amount of BGN 36.1 million, as well as the accrued 2022 impairments of non-current assets in the amount of BGN 20.8 million.





Sopharma

Effects of COVID-19 on Sopharma

Current COVID-19 pandemic has already affected all participants in the Bulgarian economy. For Sopharma, this has led to increased demand for specific groups of medicines, including quinin-based medical products for fighting COVID-19, whose export was banned temporarily by the Bulgarian minister of healthcare with the aim of guaranteeing the local needs for this medicine.